Protein Therapeutics Market to grow with a CAGR of 6.80% throgh 2030F
Increasing healthcare
infrastructure and a supportive regulatory environment are the major drivers
for the Global Protein Therapeutics Market in the forecast period
2020-2030F
According to TechSci
Research report, “Global Protein Therapeutics Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2020-2030F”, Global
Protein Therapeutics Market has valued at USD 271.26 billion in 2024 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 6.80% through 2030. This can be due to collaborations and partnerships
among leading companies with a diverse approach to merge the expertise of
individual companies and to strengthen their position in the market.
Global health crises,
such as pandemics and outbreaks of infectious diseases, can drive the demand
for protein therapeutics. Protein therapeutics are essential in the development
of vaccines. Vaccines typically contain viral or bacterial proteins, or protein
fragments, that stimulate the immune system to produce an immune response.
During a global health crisis like a pandemic, the rapid development and
distribution of vaccines are crucial to prevent the spread of the disease.
Monoclonal antibodies, a type of protein therapeutic, have been used in the
treatment of infectious diseases. For example, monoclonal antibodies have been
employed in the treatment of COVID-19 to neutralize the virus and reduce
disease severity in infected individuals. Some protein therapeutics, such as
interferons and antiviral antibodies, are used to combat viral infections
directly by interfering with viral replication and spread. Inflammatory
responses can contribute to the severity of certain infectious diseases.
Protein therapeutics, such as cytokines and immune modulators, can help
regulate and modulate the immune response during a crisis, potentially reducing
tissue damage and improving patient outcomes.
Protein treatments
provide the body with proteins in precise amounts (depending on the patient's
needs) to cure a variety of illnesses, including diabetes, anaemia, chronic
renal failure, and structural repair. Therapeutic proteins are strong,
quick-acting medications that have been shown to be particularly successful in
treating a range of disorders. Opportunities to enhance protein treatments will
persist as our knowledge of the molecular causes of disease
expands.
In June 2019, the
clinical-stage gene therapy business Nightstar Therapeutics, which specializes
in adeno-associated virus (AAV) therapies for hereditary retinal illnesses, has
been acquired by Biogen, according to a company announcement. Due to the purchase,
Biogen currently possesses two mid- to late-stage clinical assets as well as an
ophthalmology-related preclinical program. The main asset of NST is NSR-REP1,
which is being developed by the company to treat choroideremia (CHM), a
blinding, X-linked genetic retinal condition that is uncommon and degenerative.
The Rab escort protein-1 (REP-1) is encoded by the CHM gene, a loss of function
in this gene results in CHM, which mostly affects men. Patients with CHM
initially have poor night vision, and with time, progressive vision loss
eventually results in total blindness.
Browse over XX market
data Figures and spread through 110 Pages and
an in-depth TOC on "Protein Therapeutics Market”
Rising development costs
are a significant challenge in the global protein therapeutics market. The
development of protein-based therapeutics, like monoclonal antibodies, enzymes,
and vaccines, involves substantial financial investments and resource allocation.
Protein therapeutics require extensive research and development efforts, from
the initial discovery and validation of potential targets to preclinical and
clinical testing. The complexity of biologic drug development often results in
longer timelines and higher costs compared to small-molecule drugs. Protein
therapeutics typically undergo multiple phases of clinical trials, including
Phase I, Phase II, and Phase III trials. These trials involve large patient
populations, extensive data collection, and monitoring, all of which contribute
to rising costs.
Global Protein
Therapeutics Market segmentation is based on protein function, product
type, region and company
Based on product
type, monoclonal antibodies (mabs) are the fastest-growing segment in the
global protein therapeutics market. The rapid growth of mAbs is driven by their
expanding applications in oncology, autoimmune diseases, and infectious
diseases. Advances in biotechnology have improved their specificity and
efficacy, making them a preferred treatment option. The increasing prevalence
of cancer and autoimmune disorders such as rheumatoid arthritis and multiple
sclerosis further fuels demand. Biosimilar development and regulatory approvals
have accelerated market expansion, increasing accessibility and affordability.
mAbs benefit from
continuous innovation, including antibody-drug conjugates (ADCs) and bispecific
antibodies, enhancing therapeutic potential. Major pharmaceutical investments
and growing clinical trials are also contributing to rapid market growth. With
strong commercial success and expanding therapeutic indications, monoclonal
antibodies are set to dominate the protein therapeutics market in the coming
years.
Based on Region, Asia-pacific region
to fastest growth in the Global Protein Therapeutics Market. Many countries in
the Asia-Pacific region are experiencing increased healthcare spending due to
rising incomes, expanding middle-class populations, and government initiatives
to improve healthcare access. This increased funding has boosted the demand for
advanced therapies, including protein therapeutics. Like many parts of the
world, the Asia-Pacific region is also witnessing an aging population. With an
aging demographic comes a higher prevalence of age-related diseases and chronic
conditions, which often require protein-based therapies for treatment and
management. The region is facing a growing burden of chronic diseases, such as
cancer, diabetes, cardiovascular diseases, and autoimmune disorders. These
conditions often necessitate the use of protein therapeutics, including
monoclonal antibodies and cytokines, for effective treatment. Cancer rates are
on the rise in the Asia-Pacific region. As a result, the demand for cancer immunotherapies,
which often include protein-based monoclonal antibodies and targeted therapies,
has increased significantly.
Some of the major
companies operating in the Global Protein Therapeutics Market include:
·
Amgen Inc.
·
Eli Lilly and Company.
·
F. Hoffmann-La Roche
Ltd.
·
Johnson & Johnson
Services, Inc
·
Merck KGaA
·
Pfizer Inc
·
AstraZeneca Plc.
·
Teva Pharmaceutical
Industries Ltd
·
Bristol-Myers Squibb
Company
·
AbbVie Inc.
Download Free Sample Report
Customers can also
request 10% free customization on this report
“North America is expected to drive significant demand for protein
therapeutics, fueled by a strong healthcare infrastructure and increasing
prevalence of chronic diseases. The presence of well-established pharmaceutical
companies, coupled with continuous advancements in biotechnology, is
accelerating market growth. These companies are committed to improving patient
outcomes through innovative therapies, contributing to the expansion of the
global protein therapeutics market. Rising investments in research and
development, along with favorable regulatory policies, are enhancing product
availability and accessibility. As competition intensifies, the market is
poised for substantial growth during the forecast period, driven by innovation
and increasing healthcare needs" said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based Global management consulting firm.
Protein Therapeutics
Market, Segmented by Protein Function (Enzymatic & Regulatory, Protein
Diagnostics, Vaccines), by Product Type (Blood Clotting Factor, Erythropoietin,
Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies),
by region, and Competition 2020-2030F evaluated the future
growth potential of Global Protein Therapeutics Market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide innovative market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Protein Therapeutics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com